IRF5 and cancer: PDGFa and CAV1, however, were found to have an opposite enrichment in OS EVs compared to BC EVs, with enrichment in EVs from IRF5-low BC cells but enrichment in EVs from IRF5-high OS cells (Fig. 5h) Altogether, data confirm that t-dEVs from IRF5-low cancers are capable of altering the PMN specifically through alterations in myeloid immune cells, but the ability to create a PMN is not limited to immune cell trafficking and involves some alterations in extracellular matrix remodeling, migration, angiogenesis, and cell growth.